Prevalence and Progression of Osteoporosis in Patients With COPD
Background: Osteoporosis is common in patients with COPD, but its prevalence and progression are not well characterized. Concerns have been raised over the possible deleterious effect of long-term therapy with inhaled corticosteroids (ICSs) on bone density in this population. Here, we investigated t...
Gespeichert in:
| Veröffentlicht in: | Chest 2009-12, Vol.136 (6), p.1456-1465 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1465 |
|---|---|
| container_issue | 6 |
| container_start_page | 1456 |
| container_title | Chest |
| container_volume | 136 |
| creator | Ferguson, Gary T. Calverley, Peter M.A. Anderson, Julie A. Jenkins, Christine R. Jones, Paul W. Willits, Lisa R. Yates, Julie C. Vestbo, Jørgen Celli, Bartolome |
| description | Background: Osteoporosis is common in patients with COPD, but its prevalence and progression are not well characterized. Concerns have
been raised over the possible deleterious effect of long-term therapy with inhaled corticosteroids (ICSs) on bone density
in this population. Here, we investigated the long-term effects of therapy with fluticasone propionate (FP) alone, salmeterol
(SAL) alone, and a SAL/FP combination (SFC) on bone mineral density (BMD) and bone fractures in patients with moderate-to-severe
COPD in the TOwards a Revolution in COPD Health (TORCH) study.
Methods: A randomized, double-blind, parallel-group, placebo-controlled study conducted at 88 US centers involving 658 patients (a
subset of 6,184 international subjects in TORCH). Therapy with placebo, SAL (50 μg), FP (500 μg), or SFC (SAL 50 μg/FP 500
μg) twice daily was administered for 3 years. Baseline and yearly measurements of BMD at the hip and lumbar spine were performed.
The incidence of traumatic and nontraumatic bone fractures was recorded.
Results: At baseline, 18% of men and 30% of women had osteoporosis, and 42% of men and 41% of women had osteopenia based on BMD assessments.
Forty-three percent of subjects completed all testing. The changes in BMD at the hip and lumbar spine over 3 years were small.
No significant differences were observed between treatment arms (adjusted mean percent change from baseline at hip was â3.1%
for placebo, â1.7% for SAL, â2.9% for FP, and â3.2% for SFC therapy, respectively; while, the corresponding changes for the
lumbar spine were 0, 1.5%, â0.3%, and â0.3% for placebo, respectively, SAL, FP, and SFC therapy). The incidence of fractures
was low and was similar for all treatments (5.1% to 6.3%).
Conclusions: Osteoporosis is highly prevalent in patients with COPD, irrespective of gender. In the TORCH study, no significant effect
on BMD was detected for ICS therapy compared with placebo.
Trial registration: ClinicalTrials.gov Identifier: NTC00268216 |
| doi_str_mv | 10.1378/chest.08-3016 |
| format | Article |
| fullrecord | <record><control><sourceid>highwire_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1378_chest_08_3016</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>chestjournal136_6_1456</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1236-90848d3838ec024bfc740cafec1088782d6e1348c120e909c7f66b670fad652c3</originalsourceid><addsrcrecordid>eNotkF1LwzAYhYMobk4vvc8f6Hzfvm2a3inzEwbrheJlyNJkzejakXSK_97OeXU48HA4PIzdIsyRCnlnGhuHOciEAMUZm2JJmFCe0TmbAmCakCjTCbuKcQtjx1JcsgmWuUTKacruq2C_dGs7Y7nual6FfhNsjL7veO_4Kg623_ehjz5y3_FKD952Q-Sffmj4YlU9XrMLp9tob_5zxj6en94Xr8ly9fK2eFgmBlMSSQkykzVJktZAmq2dKTIw2lmDIGUh01pYpEyONNgSSlM4IdaiAKdrkaeGZiw57ZrxTAzWqX3wOx1-FII6mlB_JhRIdTQx8nDiG79pvn2wKu502-4PazqR2_4QOt0iCSUUZrmgX1CpYKo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prevalence and Progression of Osteoporosis in Patients With COPD</title><source>Alma/SFX Local Collection</source><creator>Ferguson, Gary T. ; Calverley, Peter M.A. ; Anderson, Julie A. ; Jenkins, Christine R. ; Jones, Paul W. ; Willits, Lisa R. ; Yates, Julie C. ; Vestbo, Jørgen ; Celli, Bartolome</creator><creatorcontrib>Ferguson, Gary T. ; Calverley, Peter M.A. ; Anderson, Julie A. ; Jenkins, Christine R. ; Jones, Paul W. ; Willits, Lisa R. ; Yates, Julie C. ; Vestbo, Jørgen ; Celli, Bartolome</creatorcontrib><description>Background: Osteoporosis is common in patients with COPD, but its prevalence and progression are not well characterized. Concerns have
been raised over the possible deleterious effect of long-term therapy with inhaled corticosteroids (ICSs) on bone density
in this population. Here, we investigated the long-term effects of therapy with fluticasone propionate (FP) alone, salmeterol
(SAL) alone, and a SAL/FP combination (SFC) on bone mineral density (BMD) and bone fractures in patients with moderate-to-severe
COPD in the TOwards a Revolution in COPD Health (TORCH) study.
Methods: A randomized, double-blind, parallel-group, placebo-controlled study conducted at 88 US centers involving 658 patients (a
subset of 6,184 international subjects in TORCH). Therapy with placebo, SAL (50 μg), FP (500 μg), or SFC (SAL 50 μg/FP 500
μg) twice daily was administered for 3 years. Baseline and yearly measurements of BMD at the hip and lumbar spine were performed.
The incidence of traumatic and nontraumatic bone fractures was recorded.
Results: At baseline, 18% of men and 30% of women had osteoporosis, and 42% of men and 41% of women had osteopenia based on BMD assessments.
Forty-three percent of subjects completed all testing. The changes in BMD at the hip and lumbar spine over 3 years were small.
No significant differences were observed between treatment arms (adjusted mean percent change from baseline at hip was â3.1%
for placebo, â1.7% for SAL, â2.9% for FP, and â3.2% for SFC therapy, respectively; while, the corresponding changes for the
lumbar spine were 0, 1.5%, â0.3%, and â0.3% for placebo, respectively, SAL, FP, and SFC therapy). The incidence of fractures
was low and was similar for all treatments (5.1% to 6.3%).
Conclusions: Osteoporosis is highly prevalent in patients with COPD, irrespective of gender. In the TORCH study, no significant effect
on BMD was detected for ICS therapy compared with placebo.
Trial registration: ClinicalTrials.gov Identifier: NTC00268216</description><identifier>ISSN: 0012-3692</identifier><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.08-3016</identifier><identifier>PMID: 19581353</identifier><language>eng</language><publisher>American College of Chest Physicians</publisher><ispartof>Chest, 2009-12, Vol.136 (6), p.1456-1465</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1236-90848d3838ec024bfc740cafec1088782d6e1348c120e909c7f66b670fad652c3</citedby><cites>FETCH-LOGICAL-c1236-90848d3838ec024bfc740cafec1088782d6e1348c120e909c7f66b670fad652c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Ferguson, Gary T.</creatorcontrib><creatorcontrib>Calverley, Peter M.A.</creatorcontrib><creatorcontrib>Anderson, Julie A.</creatorcontrib><creatorcontrib>Jenkins, Christine R.</creatorcontrib><creatorcontrib>Jones, Paul W.</creatorcontrib><creatorcontrib>Willits, Lisa R.</creatorcontrib><creatorcontrib>Yates, Julie C.</creatorcontrib><creatorcontrib>Vestbo, Jørgen</creatorcontrib><creatorcontrib>Celli, Bartolome</creatorcontrib><title>Prevalence and Progression of Osteoporosis in Patients With COPD</title><title>Chest</title><description>Background: Osteoporosis is common in patients with COPD, but its prevalence and progression are not well characterized. Concerns have
been raised over the possible deleterious effect of long-term therapy with inhaled corticosteroids (ICSs) on bone density
in this population. Here, we investigated the long-term effects of therapy with fluticasone propionate (FP) alone, salmeterol
(SAL) alone, and a SAL/FP combination (SFC) on bone mineral density (BMD) and bone fractures in patients with moderate-to-severe
COPD in the TOwards a Revolution in COPD Health (TORCH) study.
Methods: A randomized, double-blind, parallel-group, placebo-controlled study conducted at 88 US centers involving 658 patients (a
subset of 6,184 international subjects in TORCH). Therapy with placebo, SAL (50 μg), FP (500 μg), or SFC (SAL 50 μg/FP 500
μg) twice daily was administered for 3 years. Baseline and yearly measurements of BMD at the hip and lumbar spine were performed.
The incidence of traumatic and nontraumatic bone fractures was recorded.
Results: At baseline, 18% of men and 30% of women had osteoporosis, and 42% of men and 41% of women had osteopenia based on BMD assessments.
Forty-three percent of subjects completed all testing. The changes in BMD at the hip and lumbar spine over 3 years were small.
No significant differences were observed between treatment arms (adjusted mean percent change from baseline at hip was â3.1%
for placebo, â1.7% for SAL, â2.9% for FP, and â3.2% for SFC therapy, respectively; while, the corresponding changes for the
lumbar spine were 0, 1.5%, â0.3%, and â0.3% for placebo, respectively, SAL, FP, and SFC therapy). The incidence of fractures
was low and was similar for all treatments (5.1% to 6.3%).
Conclusions: Osteoporosis is highly prevalent in patients with COPD, irrespective of gender. In the TORCH study, no significant effect
on BMD was detected for ICS therapy compared with placebo.
Trial registration: ClinicalTrials.gov Identifier: NTC00268216</description><issn>0012-3692</issn><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNotkF1LwzAYhYMobk4vvc8f6Hzfvm2a3inzEwbrheJlyNJkzejakXSK_97OeXU48HA4PIzdIsyRCnlnGhuHOciEAMUZm2JJmFCe0TmbAmCakCjTCbuKcQtjx1JcsgmWuUTKacruq2C_dGs7Y7nual6FfhNsjL7veO_4Kg623_ehjz5y3_FKD952Q-Sffmj4YlU9XrMLp9tob_5zxj6en94Xr8ly9fK2eFgmBlMSSQkykzVJktZAmq2dKTIw2lmDIGUh01pYpEyONNgSSlM4IdaiAKdrkaeGZiw57ZrxTAzWqX3wOx1-FII6mlB_JhRIdTQx8nDiG79pvn2wKu502-4PazqR2_4QOt0iCSUUZrmgX1CpYKo</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Ferguson, Gary T.</creator><creator>Calverley, Peter M.A.</creator><creator>Anderson, Julie A.</creator><creator>Jenkins, Christine R.</creator><creator>Jones, Paul W.</creator><creator>Willits, Lisa R.</creator><creator>Yates, Julie C.</creator><creator>Vestbo, Jørgen</creator><creator>Celli, Bartolome</creator><general>American College of Chest Physicians</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20091201</creationdate><title>Prevalence and Progression of Osteoporosis in Patients With COPD</title><author>Ferguson, Gary T. ; Calverley, Peter M.A. ; Anderson, Julie A. ; Jenkins, Christine R. ; Jones, Paul W. ; Willits, Lisa R. ; Yates, Julie C. ; Vestbo, Jørgen ; Celli, Bartolome</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1236-90848d3838ec024bfc740cafec1088782d6e1348c120e909c7f66b670fad652c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ferguson, Gary T.</creatorcontrib><creatorcontrib>Calverley, Peter M.A.</creatorcontrib><creatorcontrib>Anderson, Julie A.</creatorcontrib><creatorcontrib>Jenkins, Christine R.</creatorcontrib><creatorcontrib>Jones, Paul W.</creatorcontrib><creatorcontrib>Willits, Lisa R.</creatorcontrib><creatorcontrib>Yates, Julie C.</creatorcontrib><creatorcontrib>Vestbo, Jørgen</creatorcontrib><creatorcontrib>Celli, Bartolome</creatorcontrib><collection>CrossRef</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ferguson, Gary T.</au><au>Calverley, Peter M.A.</au><au>Anderson, Julie A.</au><au>Jenkins, Christine R.</au><au>Jones, Paul W.</au><au>Willits, Lisa R.</au><au>Yates, Julie C.</au><au>Vestbo, Jørgen</au><au>Celli, Bartolome</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence and Progression of Osteoporosis in Patients With COPD</atitle><jtitle>Chest</jtitle><date>2009-12-01</date><risdate>2009</risdate><volume>136</volume><issue>6</issue><spage>1456</spage><epage>1465</epage><pages>1456-1465</pages><issn>0012-3692</issn><eissn>1931-3543</eissn><abstract>Background: Osteoporosis is common in patients with COPD, but its prevalence and progression are not well characterized. Concerns have
been raised over the possible deleterious effect of long-term therapy with inhaled corticosteroids (ICSs) on bone density
in this population. Here, we investigated the long-term effects of therapy with fluticasone propionate (FP) alone, salmeterol
(SAL) alone, and a SAL/FP combination (SFC) on bone mineral density (BMD) and bone fractures in patients with moderate-to-severe
COPD in the TOwards a Revolution in COPD Health (TORCH) study.
Methods: A randomized, double-blind, parallel-group, placebo-controlled study conducted at 88 US centers involving 658 patients (a
subset of 6,184 international subjects in TORCH). Therapy with placebo, SAL (50 μg), FP (500 μg), or SFC (SAL 50 μg/FP 500
μg) twice daily was administered for 3 years. Baseline and yearly measurements of BMD at the hip and lumbar spine were performed.
The incidence of traumatic and nontraumatic bone fractures was recorded.
Results: At baseline, 18% of men and 30% of women had osteoporosis, and 42% of men and 41% of women had osteopenia based on BMD assessments.
Forty-three percent of subjects completed all testing. The changes in BMD at the hip and lumbar spine over 3 years were small.
No significant differences were observed between treatment arms (adjusted mean percent change from baseline at hip was â3.1%
for placebo, â1.7% for SAL, â2.9% for FP, and â3.2% for SFC therapy, respectively; while, the corresponding changes for the
lumbar spine were 0, 1.5%, â0.3%, and â0.3% for placebo, respectively, SAL, FP, and SFC therapy). The incidence of fractures
was low and was similar for all treatments (5.1% to 6.3%).
Conclusions: Osteoporosis is highly prevalent in patients with COPD, irrespective of gender. In the TORCH study, no significant effect
on BMD was detected for ICS therapy compared with placebo.
Trial registration: ClinicalTrials.gov Identifier: NTC00268216</abstract><pub>American College of Chest Physicians</pub><pmid>19581353</pmid><doi>10.1378/chest.08-3016</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-3692 |
| ispartof | Chest, 2009-12, Vol.136 (6), p.1456-1465 |
| issn | 0012-3692 1931-3543 |
| language | eng |
| recordid | cdi_crossref_primary_10_1378_chest_08_3016 |
| source | Alma/SFX Local Collection |
| title | Prevalence and Progression of Osteoporosis in Patients With COPD |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T17%3A38%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-highwire_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20and%20Progression%20of%20Osteoporosis%20in%20Patients%20With%20COPD&rft.jtitle=Chest&rft.au=Ferguson,%20Gary%20T.&rft.date=2009-12-01&rft.volume=136&rft.issue=6&rft.spage=1456&rft.epage=1465&rft.pages=1456-1465&rft.issn=0012-3692&rft.eissn=1931-3543&rft_id=info:doi/10.1378/chest.08-3016&rft_dat=%3Chighwire_cross%3Echestjournal136_6_1456%3C/highwire_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19581353&rfr_iscdi=true |